PMID- 11162781 OWN - NLM STAT- MEDLINE DCOM- 20010315 LR - 20161124 IS - 0041-008X (Print) IS - 0041-008X (Linking) VI - 170 IP - 3 DP - 2001 Feb 1 TI - The time-dose-response relationship for elicitation of contact dermatitis in isoeugenol allergic individuals. PG - 166-71 AB - The elicitation response in allergic contact dermatitis is dose dependent, but the time-concentration relationship for elicitation has not previously been described. In this study 27 isoeugenol-sensitive patients participated in serial dilution patch tests with isoeugenol and a double-blinded Repeated Open Application Test (ROAT) using two concentrations of isoeugenol, 0.2 and 0.05%. Seven controls without isoeugenol allergy were also included. The participants applied 3.72 +/- 1.57 (mean +/- SD) mg/cm(2) of coded isoeugenol solutions twice a day to a 3 x 3 cm(2) area on the volar aspect of the right and left arm, respectively. For each test site the applications continued until a reaction appeared or for a maximum of 28 days. The minimal criteria for a positive reaction regarded as allergic contact dermatitis was persistent erythema at the ROAT test site. All controls were negative and 16/24 (66.7%) of the included isoeugenol-sensitive subjects showed a positive ROAT to the 0.2% solution within the study period (Fisher's test, p = 0.0024). Ten of the positive patients also reacted to the 0.05% solution. The median number of days until a positive reaction to the 0.2% solution was 7 days and was 15 days for the 0.05% solution. There was a highly significant correlation between the patients' patch test threshold and the number of days until a positive ROAT. In conclusion, the time until an isoeugenol allergic individual reacts in a ROAT depends on the individual sensitivity as well as the exposure concentrations; for low concentrations of the allergen or low degree of sensitivity, the allergic contact dermatitis may develop after several weeks of exposure. Therefore, a negative ROAT after 7 days may be a false negative. CI - Copyright 2001 Academic Press. FAU - Andersen, K E AU - Andersen KE AD - Department of Dermatology, Odense University Hospital, University of Southern Denmark, Odense, Denmark. FAU - Johansen, J D AU - Johansen JD FAU - Bruze, M AU - Bruze M FAU - Frosch, P J AU - Frosch PJ FAU - Goossens, A AU - Goossens A FAU - Lepoittevin, J P AU - Lepoittevin JP FAU - Rastogi, S AU - Rastogi S FAU - White, I AU - White I FAU - Menne, T AU - Menne T LA - eng PT - Clinical Trial PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Toxicol Appl Pharmacol JT - Toxicology and applied pharmacology JID - 0416575 RN - 0 (Allergens) RN - 0 (Perfume) RN - 3T8H1794QW (Eugenol) RN - 5M0MWY797U (isoeugenol) SB - IM MH - Administration, Topical MH - Allergens/*adverse effects MH - Denmark MH - Dermatitis, Contact/*etiology MH - Dose-Response Relationship, Drug MH - Double-Blind Method MH - Drug Hypersensitivity/*etiology MH - Eugenol/administration & dosage/*adverse effects/analogs & derivatives MH - Female MH - Humans MH - Male MH - Middle Aged MH - Patch Tests MH - *Perfume/adverse effects MH - Time Factors EDAT- 2001/02/13 11:00 MHDA- 2001/03/17 10:01 CRDT- 2001/02/13 11:00 PHST- 2001/02/13 11:00 [pubmed] PHST- 2001/03/17 10:01 [medline] PHST- 2001/02/13 11:00 [entrez] AID - S0041-008X(00)99095-1 [pii] AID - 10.1006/taap.2000.9095 [doi] PST - ppublish SO - Toxicol Appl Pharmacol. 2001 Feb 1;170(3):166-71. doi: 10.1006/taap.2000.9095.